drugset / Trial / NCT05588531

Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers

NCT05588531

Phase 1 Completed 66 enrolled Nanjing Yoko Biomedical Co., Ltd.
RandomizedFactorialTriple-blindBasic science

Summary

To evaluate the safety and tolerability of multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.

Timeline

Start
2021-12-20
Primary completion
2022-04-02
Completion
2022-04-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefepime Small molecule 2 g Intravenous
Comparator YK-1169 Unknown 0.5 g Intravenous
Comparator YK-1169 Unknown 1.25 g Intravenous
Comparator YK-1169 Unknown 2.5 g Intravenous
Comparator YK-1169 Unknown 3.75 g Intravenous
Comparator YK-1169 Unknown 5 g Intravenous
Comparator avibactam Small molecule 0.5 g Intravenous

Indications

No indication recorded.